Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues. Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…
Korea Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for longer. That was the message from nearly every biotech executive PharmaBoardroom spoke with in a series of recent interviews in…
Korea James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong service-oriented culture. He outlines the company’s expansion plans, technological differentiation, and support for Korea’s emerging biotech ecosystem, while reflecting on…
See our Cookie Privacy Policy Here
